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Major abdominal surgery can increase IP. Intraoperatively, gut barrier function may be compromised by hemorrhage, hypoxia, ischemia-reperfusion injury, and even mechanical manipulation. Protection of IP in the perioperative period is, therefore, of the utmost importance. 1, 4 Animal and human studies have focused on the protection of IP after surgery during the recent years. Unfortunately, although several agents have been tested, very few of them have shown encouraging results. 4 Probiotics may play a protective role in the intestinal barrier function. 3 They can balance the aberrant enteric microflora, protect epithelial tight junctions, have a trophic effect on gut mucosa, stimulate mucosal immunity, and exert an anti-inflammatory action. 3, 5 Although there is a great body of experimental studies that supports the protective action of probiotics on intestinal mucosa, there is a lack of data suggesting that they can modify IP in humans.
Erythropoietin also has a trophic effect on the bowel and interacts with mediators of inflammation reducing the levels of overexpressed proinflammatory cytokines and decreasing cytokine-induced apoptosis. 6 Moreover, recent data have shown that it can promote angiogenesis, reduce oxidative stress, and accelerate wound healing. 7 The potential effect of Saccharomyces boulardii or erythropoietin on IP in the perioperative period has not been evaluated. In a study of 8 patients undergoing elective major abdominal surgery, we observed a postoperative IP reduction in those receiving S. boulardii orally (n = 4) and those administered per os erythropoietin (n = 4). Our very preliminary results implied that, compared with preoperative values, postoperative IP was reduced in patients administered S. boulardii (0.03 vs. 0.06, P = 0.05) as well as in those receiving erythropoietin (0.08 vs. 0.16, P = 0.04). Although it is early to draw conclusions and our findings are very preliminary, these results seem promising.
Preservation The APRI and the RVR To the Editor:
We read with interest the recent letter by Colletta et al, 1 which specifically mentioned our study in this journal.
2 It seems that the author's thesis is that because the rapid viral response (RVR) is such a useful tool, almost all patients with chronic hepatitis C virus (HCV) should be treated, and therefore, hepatic fibrosis markers that can distinguish mild from significant fibrosis are not needed. The authors go on to advocate the use of the liver biopsy and/or transient elastography to distinguish patients with cirrhosis because they may require longer therapy.
Our paper was written before the widespread acceptance of the RVR as a useful test to predict sustained viral response (SVR). Therefore, reassessment of our findings and the role of the aspartate aminotransferase/platelet ratio index (APRI) and similar hepatic fibrosis markers in relation to RVR seem appropriate.
Although we agree that the RVR is a terrific clinical management tool, we would argue that it does not diminish the usefulness of the APRI or any other hepatitis fibrosis marker. Although shorter periods of therapy for patients with RVR make universal HCV therapy attractive, it is a concept that remains controversial. There is evidence from the ACCELERATE trial that the relapse rate is higher in genotype 2 and 3 patients that are only treated for 16 weeks. 3 In support of a shorter duration of therapy for genotype 1 patients, the authors cite an article by Jensen et al, which was a retrospective analysis of a previous multicenter study of ribavirin dosage and length of therapy. 5 This study does not recommend 24 weeks of therapy for genotype 1 rapid responders, but rather noted that early response identified those who had SVR with shorter therapy. We are not aware of any broad recommendations derived from large prospective studies that advocate only 24 weeks of antiviral therapy in genotype 1 patients. Moreover, evidence from Europe suggests that a patient with genotype 1 needs to have a negative HCV RNA for at least 36 weeks to achieve a 90% chance for a SVR. 6 It is also important to remember that only about one-fourth of patients have RVR. 4 Therefore, even if one is a proponent for shorter therapy in rapid responders, the bulk of genotype 1 patients will still require a year of therapy.
In the United States, treatment for hepatitis C remains quite expensive and many patients have co-morbidities that make treatment problematic. Also, evidence suggests that only 10% of patients with HCV will suffer liverrelated mortality. 7 Therefore, until pegylated interferon and ribavirin are replaced, it is unlikely that there will be consensus recommendations to routinely treat all patients with HCV. Thus, it seems prudent to try to identify patients most likely to benefit from therapy. Unfortunately, some patients and health care systems in the United States are burdened with limited resources. We care for a large number of patients in the Texas Department of Corrections who are infected with hepatitis C. On the basis of the findings from our prospective study, we use the APRI for screening. For genotype 1 patients without contraindications, if the APRI is r0.42 they are not treated or evaluated further. Patients with an APRI from 0.42 to 1.19 undergo a liver biopsy and subsequent treatment if a fibrosis stage F2 or more (Batts Ludwig classification) and those with an APRI Z1.2 receive treatment. Because transient elastography is not approved for use in the United States, we cannot comment on its use in a treatment algorithm.
Ultimately, we think that the greatest use of the APRI and other hepatic fibrosis markers may be in the longitudinal management of patients with chronic hepatitis C and the prediction of those at higher risk for complications such as hepatocellular carcinoma.
